Optimal management of metastatic melanoma: current strategies and future directions - Wikidata - thesis-toulmin - TriplyDB

Optimal management of metastatic melanoma: current strategies and future directions

Optimal management of metastatic melanoma: current strategies and future directions

http://www.wikidata.org/entity/Q26997338

about

Comparison of cytotoxicity between extracts of Clinacanthus nutans (Burm. f.) Lindau leaves from different locations and the induction of apoptosis by the crude methanol leaf extract in D24 human melanoma cells.Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2 SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.Anorectal melanoma metastatic to the breast: a case report and review of the literature.Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways Rationale for combining immunotherapy with chemotherapy.Metastatic melanoma of the gallbladder: report of two cases and a review of the literature.Recent developments in nanomedicine for melanoma treatment.Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells Hibiscus sabdariffa leaf polyphenolic extract induces human melanoma cell death, apoptosis, and autophagy.STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma.EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma.Anorectal mucosal melanoma.Melanoma treatment in review.Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma.Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.

P2860

Q36137750-7EE7DDA4-5AF5-409A-B9BA-DFB95CDAE44B Q36194074-E059B175-F05B-41F2-9A11-95F341FBE219 Q36962895-329DC4C2-2FB6-4A46-B6CB-1B11F0AA4BD5 Q37179412-1A62094B-2F67-4D19-A2A7-C138FF252229 Q37747447-3E2366BE-6758-46BD-AE1A-934A2C1EE23D Q38389326-AEE1836E-FC91-4CC2-99A1-BAC7A3298D51 Q38451992-15295E86-08D2-454E-9F6E-32E07D9CC8CE Q38740124-823AF840-1C26-4A67-8EC4-428429263A27 Q38870044-8B06010F-E750-40A3-A816-645F484A488A Q38908250-DC11B433-7B7D-4F7F-A11F-4DC6BF41ADD5 Q39023307-3E9A761B-A4FE-4E9D-BB23-0A636BA42D39 Q47150730-F222D7CE-2E28-4A9A-AA54-A612E7C1CC81 Q52680468-17596BBF-173A-446E-8B33-2CC7E19688BE Q55217220-625F0E8A-C945-42AB-BBFA-6A4F6DB0BB1E Q55266129-AB64C056-0EF0-4EFA-807E-9B06B5B568FB Q55308518-81AE15AC-3C9A-42D7-9179-B86A2D63CF77

P2860

Optimal management of metastatic melanoma: current strategies and future directions

http://www.wikidata.org/entity/Q26997338

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Optimal management of metastatic melanoma: current strategies and future directions

@ast

Optimal management of metastatic melanoma: current strategies and future directions

@en

Optimal management of metastatic melanoma: current strategies and future directions

@nl

type

label

Optimal management of metastatic melanoma: current strategies and future directions

@ast

Optimal management of metastatic melanoma: current strategies and future directions

@en

Optimal management of metastatic melanoma: current strategies and future directions

@nl

prefLabel

Optimal management of metastatic melanoma: current strategies and future directions

@ast

Optimal management of metastatic melanoma: current strategies and future directions

@en

Optimal management of metastatic melanoma: current strategies and future directions

@nl

P1433

Q26997338-A8132D78-E50B-4FE8-8294-B842F6692C40

P1476

Q26997338-53F4C2BD-0173-41EA-972F-2120F9F4C605

P2093

Q26997338-1D6CD014-40BE-4B94-A03A-84A7A6D9A40D

Q26997338-9105B9C3-179B-4EA1-85DB-267F42AFBF02

Q26997338-A280A64B-4B3D-495E-9EE8-FA1D2E83FD3E

Q26997338-B43FDB02-34B2-4586-8537-E108BFD6F9A6

Q26997338-D9B51B43-1BEE-452C-8F1C-72FBEBB60AB1

Q26997338-E185894C-61A7-42A0-A932-1EA11EC839E4

P2860

Q26997338-0174B202-CAC0-40CF-A669-7A63D8A07995

Q26997338-025EE78A-27B4-4F7F-BFA0-1775C6ED0FC2

Q26997338-0942A319-E0DB-4FAF-9A9C-C229EB7CA768

Q26997338-0B47FA90-C60B-4EBF-9AC5-34C598075CA3

Q26997338-11BE783F-5D6B-4B9A-A79B-D236DF7A5469

Q26997338-11E7FFAE-69D3-44A4-A1C1-313908F30CD7

Q26997338-13C0E3E5-100D-492E-8981-A0524084E85C

Q26997338-153AC4FF-815E-4D7B-92B4-49AB39C6ED42

Q26997338-15AA59E1-FA11-4E53-9971-F48DAE529ED3

Q26997338-1797F4E4-5BDF-440A-9FE0-69ECEDF7CCFF

P2888

Q26997338-A2B0B5A0-36E7-427B-9490-B14EA67A4254

P304

Q26997338-9CB60701-706F-4A93-BCEF-66016B54347C

P31

Q26997338-45C32764-8AFC-4897-A467-776F03BFB7ED

P3181

Q26997338-309E83B1-C647-4356-8BE5-EF8FAF090303

P356

Q26997338-D641043F-4F38-4203-99C4-C540422D56D3

P407

Q26997338-CE63E2C9-072D-4C69-90B1-F65F78476039

P433

Q26997338-746C8D98-4763-49AB-924F-5EB732E36673

P478

Q26997338-75DA6F54-5B8F-4246-92C2-304D880E1F5E

P577

Q26997338-604E75E3-8208-4804-BCBE-4230F4621A7E

P6179

Q26997338-93BB71AF-EF36-4C3A-809A-301B67FD78BF

P698

Q26997338-E0425BF1-F381-42D1-BE03-5FBDA154B616

P932

Q26997338-FBE3C0D3-D669-4150-8FBC-77B342B5B073

P3181

P356

S40257-013-0025-9

P1433

American Journal of Clinical Dermatology

P1476

Optimal management of metastatic melanoma: current strategies and future directions

@en

P2093

Carl Ruby

http://www.w3.org/2001/XMLSchema#string

Howard L. Kaufman

http://www.w3.org/2001/XMLSchema#string

Lindsay Petersen

http://www.w3.org/2001/XMLSchema#string

Marta Batus

http://www.w3.org/2001/XMLSchema#string

Salman Waheed

http://www.w3.org/2001/XMLSchema#string

Steven D. Bines

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Treatment of metastatic melanoma: an overview

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

Cancer regression in patients after transfer of genetically engineered lymphocytes

P2888

s40257-013-0025-9

P304

179-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3458679

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S40257-013-0025-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1038787795

http://www.w3.org/2001/XMLSchema#string

P698

23677693

http://www.w3.org/2001/XMLSchema#string

P932

3913474

http://www.w3.org/2001/XMLSchema#string